Cocrystal Pharma (NASDAQ:COCP) Releases Quarterly Earnings Results, Beats Expectations By $0.13 EPS

Cocrystal Pharma (NASDAQ:COCP) posted its earnings results on Thursday. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.13, reports.

Cocrystal Pharma Stock Down 6.7 %

Shares of NASDAQ COCP opened at $1.40 on Friday. The firm has a market cap of $14.24 million, a price-to-earnings ratio of -0.70 and a beta of 1.34. Cocrystal Pharma has a 52-week low of $1.33 and a 52-week high of $3.29. The company’s 50-day simple moving average is $1.51 and its 200-day simple moving average is $1.69.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Cocrystal Pharma in a research report on Wednesday, March 20th.

Institutional Investors Weigh In On Cocrystal Pharma

A hedge fund recently bought a new stake in Cocrystal Pharma stock. Susquehanna International Group LLP purchased a new position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 20,728 shares of the company’s stock, valued at approximately $41,000. Susquehanna International Group LLP owned approximately 0.20% of Cocrystal Pharma as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 6.72% of the company’s stock.

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.